母子导管技术开通透析患者慢性中心静脉闭塞病变的疗效与安全性
本研究回顾性分析81例血液透析合并中心静脉狭窄或闭塞患者,采用母子导管技术配合球囊扩张及支架植入开通病变。病变成功率在狭窄组为100%、闭塞组为95.6%,无严重并发症或手术相关死亡。随访中位6个月,6个月和12个月一期通畅率分别为狭窄组89.7%和54.2%、闭塞组81.0%和47.1%。
要点
- 母子导管技术可为透析患者慢性中心静脉闭塞病变提供有效且安全的开通方法。
- 闭塞组病变成功率95.6%,无严重并发症或手术相关死亡。
- 6个月和12个月一期通畅率在狭窄组为89.7%和54.2%,闭塞组为81.0%和47.1%。
核心结论
- 母子导管技术辅助的经皮治疗是血液透析患者慢性中心静脉闭塞病变开通的有效且安全的方法。
研究设计与样本
- 回顾性收集连续接受经皮球囊扩张和支架植入治疗的 symptomatic 中心静脉狭窄或闭塞的血液透析患者。
- 共纳入36例症状性中心静脉狭窄患者和45例完全中心静脉闭塞患者。
- 闭塞病变采用造影导管套入指引导管的母子导管技术通过。
主要发现
- 闭塞组糖尿病肾病患病率高于狭窄组(24.4% vs 5.6%;P < .05)。
- 狭窄组病变成功、器械成功和手术成功分别为36例(100%)、1例(100%)和36例(100%)。
- 闭塞组病变成功、器械成功和手术成功分别为43例(95.6%)、11例(100%)和43例(95.6%)。
- 两组均无严重并发症或手术相关死亡。
- 随访中位6个月,6个月和12个月一期通畅率在狭窄组为89.7%和54.2%,在闭塞组为81.0%和47.1%;6个月和12个月辅助一期通畅率在狭窄组为100%,在闭塞组为91.2%。
临床怎么用
- 对于血液透析患者症状性中心静脉狭窄或闭塞,可考虑采用母子导管技术辅助经皮球囊扩张和支架植入开通病变。
局限性
- 本研究为回顾性设计,样本量有限(共81例),随访中位时间仅6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is no optimal treatment for central vein occlusive disease that remains a major contributor to vascular access impairment. This study aimed to review the outcomes of percutaneous treatment with a mother-child technique in the treatment of symptomatic central venous stenosis (CVS) and central venous occlusion (CVO) in patients on hemodialysis. METHODS: Data were collected retrospectively and included all consecutive patients with CVS or CVO who were treated with percutaneous angioplasty and stenting. The occlusive lesions were crossed using the mother-child technique with an angiographic catheter-in-guiding catheter system. RESULTS: A total of 36 patients with symptomatic CVS and 45 patients with total CVO were included. The average age and gender composition were similar between the two groups. Patients with CVO had higher prevalence of diabetic nephropathy than CVS (24.4% vs 5.6%; P < .05). Lesion success, device success, and procedural success were achieved in 36 (100%), 1 (100%), and 36 (100%) patients in the CVS group and in 43 (95.6%), 11 (100%), and 43 (95.6%) patients in the CVO group, respectively. There were no severe complications or procedure-related deaths in either group. During follow-up (median, 6 months), the primary patency rates were 89.7% (CVS) and 81.0% (CVO) at 6 months and were 54.2% (CVS) and 47.1% (CVO) at 12 months. The assisted primary patency rates were 100% (CVS) and 91.2% (CVO) at 6 and 12 months. CONCLUSIONS: With extra backup support of the mother-child technique, percutaneous treatment provides an effective and safe method for recanalization of chronic venous occlusion in patients on hemodialysis.
引用
- Wan Z, Lai Q, Zhou Y, et al. Efficacy and safety of a mother-child technique for recanalization of chronic central venous occlusive disease in hemodialysis patients. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31848120. doi:10.1016/j.jvsv.2019.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。